Close menu




June 26th, 2023 | 08:50 CEST

Best conditions for a summer rally - Defence Therapeutics, SMA Solar, Rheinmetall

  • Biotechnology
  • armaments
  • Energy
Photo credits: pixabay.com

The German stock market reflects the current weather situation - bright to cloudy, with occasional dark clouds moving in, bringing thunderstorms and heavy rain. In the past few days, lightning struck companies such as Helma Eigenheimbau, Siemens Energy and Lanxess, which was reflected in price losses of well over 10%. Other companies were spared from the storm front and should continue to enjoy their place in the sun due to the positive news.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013 , SMA SOLAR TECHNOL.AG | DE000A0DJ6J9 , RHEINMETALL AG | DE0007030009

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Rheinmetall - Orders from all directions

    It is well known that the integrated, international technology group has emerged as one of, if not the main beneficiary of the Ukraine war. The DAX member reports almost weekly on new orders related to the conflict. The latest deal with the German government is the delivery of an additional 20 Marder infantry fighting vehicles to the Ukrainian war zone. Moreover, Rheinmetall could provide 60 more Marder vehicles. In the course of the ring swap procedure initiated by the German government, Greece will also receive 40 armoured infantry fighting vehicles from the Düsseldorf-based company.

    In addition to the defence business, Rheinmetall's hydrogen strategy was also confirmed. The Group received two further orders for the delivery of fuel cell components. In a press release, Rheinmetall announced that the total volume for the two orders for cathode and shut-off valves from North America is in the mid double-digit million euro range. With these two orders, the total order value that Rheinmetall has achieved with cathode valves now reaches the triple-digit million euro range and underpins the successes in the context of the Group's hydrogen strategy, which aims to further expand its position in the field of alternative propulsion systems.

    Due to the consistently positive news flow, the sell signal generated a few weeks ago could be stopped for the time being with the break of the downward trend formed since October 2022. However, the still negative chart picture will only brighten once the resistance at EUR 265.70 is overcome. In a recent report, analysts at Deutsche Bank Research maintained their price target on Rheinmetall shares at EUR 275 and issued a "buy" rating on the stock.

    Defence Therapeutics - Initiates roll-out

    The biopharmaceutical company published two important milestones within a week, significantly brightening the share's chart situation with the break of the downward trend established since January at CAD 3.02. At its peak, the price reached CAD 3.30 but is now likely to test the breakout level again, which should offer an attractive entry opportunity in the long term.

    Firstly, the Canadians applied for patent protection for their broadly applicable platform technology for 157 countries for the intracellular administration of various active ingredients and vaccines, including polynucleotides, recombinant proteins and nucleoprotein complexes according to the PCT standard. The patent, filed by Defence Therapeutics, incorporates ACCUM™'s versatile properties and serves both as a drug enhancer for mRNA vaccines and as a vehicle for innovative techniques such as CRISPR, also known as "gene scissors". CRISPR makes it possible to remove faulty genetic information from existing DNA and replace it with new information.

    On the other hand, significant successes were reported in research with the chemotherapeutic AccuTOX. The compound was exposed to temperature fluctuations, light, and humidity. The tests showed that the active ingredient is stable at temperatures ranging from -20 °C to 5 °C. A pre-clinical study on animals has been completed, showing 100% efficacy in treating lymphoma. This brings Defence Therapeutics ever closer to the approval of AccuTOX for a Phase I trial, which is expected to be conducted at the renowned City of Hope Hospital.

    SMA Solar - Strong growth

    Germany's best-known manufacturer of inverters for grid-connected photovoltaic systems made a strong statement with its first-quarter results for the current fiscal year 2023. The SMA Group posted a remarkable sales increase of 66.5% in the period from January to March 2023, corresponding to EUR 367.2 million. This positive development was observed in all three business segments. Particularly noteworthy is the Home Solutions segment, which increased its turnover to EUR 163.3 million after EUR 62.6 million in the same quarter of the previous year, representing an increase of more than 150%.

    The Commercial & Industrial Solutions segment also recorded a significant increase in turnover. Here revenue increased by 41.9% to EUR 80.2 million, compared to EUR 56.5 million in the same quarter of the previous year. In the Large Scale & Project Solutions segment, revenues reached EUR 123.7 million, compared to EUR 101.5 million in the first 3 months of 2022. Another factor that contributed to this positive overall development was the storage technology, digital energy services and green hydrogen production sectors.

    In the wake of the positive figures, the SMA share shot up by around 27% and ended the trading week at EUR 102. The previous high for the year was marked in May at EUR 111.40. The analyst firm Jefferies left its rating for SMA Solar at "buy" with a price target of EUR 120 after setting higher annual targets.


    Rheinmetall continues to receive a constant stream of orders, filling up its order books. SMA was able to shine with strong figures. The share of Defence Therapeutics broke out of its downtrend with two positive news releases in one week.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.

    Read

    Commented by André Will-Laudien on May 16th, 2024 | 07:00 CEST

    Attention: Here we go! Hydrogen and uranium on the rise: Plug Power, Nel ASA, Kraken Energy and Siemens Energy in focus

    • Mining
    • Uranium
    • Hydrogen
    • renewableenergies
    • Energy

    It has finally happened! After months of sell-offs in hydrogen shares, there was a sigh of relief across the sector the day before yesterday. The reason: industry leader Plug Power received a government guarantee of USD 1.66 billion as backing for the construction of six-megawatt sites nationwide to create an initial hydrogen infrastructure. The Department of Energy (DOE) is thus demonstrating that the US is serious about investing in alternative energies. The decision boosted the entire energy sector, with uranium also continuing its recent upward trend. Where do the opportunities lie for investors?

    Read

    Commented by Armin Schulz on May 15th, 2024 | 06:45 CEST

    Volkswagen, Desert Gold, RWE - There is significant upside potential here

    • Mining
    • Gold
    • Electromobility
    • Energy

    The search for stocks with upside potential is like a treasure hunt in the depths of the financial markets. It combines analysis and intuition to find companies with solid fundamentals, innovation, and a good market environment for growth. Investors must show foresight and recognize many factors that make a share special. We have selected three candidates who have not stood out in recent months but still have significant catch-up potential.

    Read